Completed PHASE1 INTERVENTIONAL 1-arm NCT03886103

Pharmacokinetics and Metabolism of (14C)-Labelled PXL770

Pharmacokinetics and Metabolism of [14C]-Labelled PXL770 Following a Single Oral Administration in Healthy Male Volunteers

Sponsor: Poxel SA

Conditions Healthy

Interventions 14C labeled PXL770

Updated 4 times since 2019 Last updated: Mar 20, 2019 Started: Feb 6, 2019 Primary completion: Mar 15, 2019 Completion: Mar 15, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03886103, this PHASE1 trial focuses on Healthy and remains completed. Sponsored by Poxel SA, it has been updated 4 times since 2019, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Apr 2019 — Jan 2021 [monthly]

Completed PHASE1

First recorded

Feb 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Poxel SA

Data source: Poxel SA

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Nottingham, United Kingdom